Aarvik Therapeutics

Aarvik Therapeutics is a private oncology biotechnology company based in Hayward, California, focused on engineering next-generation precision medicines for cancer. The company was launched in 2021 and was formerly known as Aarkus Therapeutics before adopting the Aarvik name. Its core strategy centers on proprietary modular antibody-drug conjugate technologies, including the MUTTA platform for multi-epitope, tetravalent antibodies and the AQUALINK linker-payload platform, with the aim of improving therapeutic index versus conventional ADCs. Aarvik has highlighted preclinical programs in solid tumors and has partnered with ArriVent BioPharma on a licensed ADC program, ARR-002, targeting ovarian and endometrial cancers. The company remains a private, platform-focused preclinical biotech advancing an oncology ADC pipeline.